Source: https://www.reanimatology.com/rmt/article/view/257
Timestamp: 2019-04-19 05:01:59+00:00

Document:
3. Архипенко Ю. В., Сазонтова Т. Т., Меерсон Ф. З. Разнонаправленное действие адаптации к непрерывистой и прерывистой гипоксии на антиоксидантные ферменты и уровень продуктов перекисного окисления липидов. Hypoxia Medical J. 1994; 3; 11 — 15.
4. Murry C. E., Jennings R. B., Reimer K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74 (5): 1124—1136.
5. Kloner R. A, Bolli R., Marban E. et al. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation 1998; 97 (18): 1848—1867.
6. Miura T., Goto M., Urabe K. et al. Does myocardial stunning contribute to infarct size limitation by ischemic preconditioning? Circulation 1991; 84 (6): 2504—2512.
7. Murry C. E., Richard V. J., Jennings R. B., Reimer K. A. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am. J. Physiol. 1991; 260 (3 Pt 2): H796—H804.
8. Juhaszova M., Zorov D. B., Kim S. H. et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mito-chondrial permeability transition pore. J. Clin. Invest. 2004; 113 (11): 1535—1549.
10. Marber M., Walker D, Yellon D. Ischaemic preconditioning. BMJ 1994; 308 (6920): 1—2.
11. Zager R. A., Iwata M., Burkhart K. M, Schimpf B. A.Postischemic acute renal failure protects proximal tubules from O2 deprivation injury, possibly by inducing uremia. Kidney Int. 1994; 45 (6): 1760—1768.
12. Zager R. A., Burkhart K. M., Gmur D. J.Postischemic proximal tubular resistance to oxidant stress and Ca ionophore-induced attack. Implication for reperfusion injury. Lab. Invest. 1995; 72 (5): 592—600.
13. Lee H. T., Emala C. W.Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A (I) and A (3) receptors. Am. J. Physiol. Renal. Physiol. 2000; 278 (3): F380—F387.
14. Bellomo R., Bonventre J., Macias W., Pinsky M.Management of early acute renal failure: Focus on post-injury prevention. Curr. Opin. Crit. Care 2005; 11 (6): 542—547.
15. Rudiger Y. A., Kang K. J., Sindram D. et al.Comparison of ischemic preconditioning and intermittent and continuous inflow occlusion in the murine liver. Ann. Surg. 2002; 235 (3): 400—407.
16. Clavien P. A, Yadav S., Sindram D., Bentley R. C.Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann. Surg. 2000; 232 (2): 155—162.
17. Chouker A., Schachtner T., Schauer R. et al.Effects of pringle manoeuvre and ischaemic preconditioning on haemodynamic stability in patients undergoing elective hepatectomy: a randomized trial. Br. J. Anaesth. 2004; 93 (2): 204—211.
18. Hotter G., Closa D., Prados M. et al.Intestinal preconditioning is mediated by a transient increase in nitric oxide. Biochem. Biophys. Res. Commun. 1996; 222 (1): 27—32.
19. Aksoyek S., Cinel I., Avlan D. et al.Intestinal ischemic preconditioning protects the intestine and reduces bacterial translocation. Shock 2002; 18 (5): 476—480.
20. Tamion F., Richard V., Lacoume Y., Thuillez C.Intestinal preconditioning prevents systemic infiammatory response in hemorrhagic shock. Role of HO-1. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 283 (2): G408—G414.
21. Kaul T. K., Fields B. L., Riggins L. S. et al.Adult respiratory distress syndrome following cardiopulmonary bypass: incidence, prophylaxis and management. J. Cardiovasc. Surg. (Torino) 1998; 39 (6): 777—781.
22. de Perrot M., Liu M., Waddell T. K., Keshavjee S.Ischemia-reperfusion-induced lung injury. Am. J. Respir. Crit. Care Med. 2003; 167 (4): 490—511.
23. Kitagawa K., Matsumoto M., Tagaya M. et al.Ischemic tolerance phenomenon found in the brain. Brain Res. 1990; 528 (1): 21—24.
24. Kirino T.Ischemic tolerance. J. Cereb. Blood Flow Metab. 2002; 22 (11): 1283—1296.
25. Sitzer M., Foerch C., Neumann-Haefelin T. et al.Transient ischemic attack preceding anterior circulation infarction is independently associated with favourable outcome. J. Neurol. Neurosurg. Psychiatry 2004; 75 (4): 659—660.
26. Cohen M. V., Baines C. P., Downey J. M.Ischemic preconditioning: from adenosine receptor to KATP channel. Annu. Rev. Physiol. 2000; 62: 79—109.
27. Jennings R. B., Sebbag L., Schwartz L. M. et al.Metabolism of preconditioned myocardium: effect of loss and reinstatement of cardioprotec-tion. J. Mol. Cell Cardiol. 2001; 33 (9): 1571 — 1588.
28. Charlat M. L., O&#8217;Neill P. G., Hartley C. J. et al.Prolonged abnormalities of left ventricular diastolic wall thinning in the «stunned» myocardium in conscious dogs: time course and relation to systolic function. J. Am. Coll. Cardiol. 1989; 13 (1): 185—194.
29. Murry C. E., Richard V. J., Reimer K. A., Jennings R. B.Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ. Res. 1990; 66 (4): 913—931.
30. Fleet W. F., Johnson T. A., Graebner C. A., Gettes L. S.Effect of serial brief ischemic episodes on extracellular K+, pH, and activation in the pig. Circulation 1985; 72 (4): 922—932.
31. Armstrong S., Downey J. M., Ganote C. E.Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. Cardiovasc. Res. 1994; 28 (1): 72—77.
32. Pain T., Yang X. M., Critz S. D. et al.Opening of mitochondrial K (ATP) channels triggers the preconditioned state by generating free radicals. Circ. Res. 2000; 87 (6): 460—466.
33. Grover G. J., D&#8217;Alonzo A. J., Dzwonczyk S. et al.Preconditioning is not abolished by the delayed rectifier K+ blocker dofetilide. Am. J. Physiol. 1996; 271 (3 Pt 2): H1207—H1214.
34. Yao Z., Cavero I., Gross G. J.Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia. Am. J. Physiol. 1993; 264 (2 Pt 2): H495—H504.
35. AuchampachJ. A., Grover G. J., Gross G. J.Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc. Res. 1992; 26 (11): 1054—1062.
36. Garlid K. D., Paucek P., Yarov-Yarovoy V. et al.The mitochondrial KATP channel as a receptor for potassium channel openers. J. Biol. Chem. 1996; 271 (15): 8796—8799.
37. GarlidK. D., Paucek P., Yarov-Yarovoy V. et al.Cardioprotective effect of dia-zoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ. Res. 1997; 81 (6): 1072—1082.
38. Jennings R. B.Role of protein kinase C in preconditioning with ischemia against lethal cell injury. Basic Res. Cardiol. 1997; 92 (Suppl 2): 40—42.
39. Ping P., Zhang J, Qiu Y. et al.Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ. Res. 1997; 81 (3): 404—414.
40. Ping P., ZhangJ., Zheng Y. T. et al.Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ. Res. 1999; 85 (6): 542—550.
41. Ping P., Takano H., ZhangJ. et al.Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ. Res. 1999; 84 (5): 587—604.
42. Downey J. M., Yellon D. M.The biology of preconditioning. In: Heyndrickx G. R., Vatner S. F., Wijns W. (eds.). Stunning, hibernation and preconditioning: clinical pathophysiology of myocardial ischemia. Philadelphia: Lippincott-Raven Publishers; 1997. 105—220.
43. Vahlhaus C., Schulz R., Post H. et al.No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ. Res. 1996; 79 (3): 407—414.
44. Kwok J. B., Hallupp M., Loy C. T. et al.GSK3B polymorphisms alter transcription and splicing in Parkinson&#8217;s disease. Ann. Neurol. 2005; 58 (6): 829—839.
45. Zorov D. B., Juhaszova M., Yaniv Y. et al.Regulation and pharmacology of the mitochondria permeability transition pore. Cardiovasc. Res. 2009; 83 (2): 213—225.
46. Schaffer S. W., Suleiman M.-S.Mitochondria. New York: Springer Science; 2007. 349.
47. Kroemer G., Dallaporta B., Resche-Rigon M.The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol. 1998; 60: 619—642.
48. Kowaltowski A. J., Castilho R. F., Vercesi A. E.Mitochondrial permeability transition and oxidative stress. FEBS Lett. 2001; 495 (1—2): 12—15.
49. Gottlieb R. A.Mitochondria: execution central. FEBS Lett. 2000; 482 (1—2): 6—12.
50. Crompton M.The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 1999; 341 (Pt 2): 233—249.
51. Skulachev V. P.How proapoptotic proteins can escape from mitochondria? Free Radic. Biol. Med. 2000; 29 (10): 1056—1059.
52. Koc E. C., Burkhart W., Blackburn K. et al.Identification of four proteins from the small subunit of the mammalian mitochondrial ribosome using a proteomics approach. Protein Sci. 2001; 10 (3): 471—481.
53. Haunstetter A., Izumo S.Future perspectives and potential implications of cardiac myocyte apoptosis. Cardiovasc. Res. 2000; 45 (3): 795—801.
54. Susin S. A., Lorenzo H. K., Zamzami N. et al.Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397 (6718): 441—446.
55. Skulachev V. P.Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Lett. 1996; 397 (1): 7—10.
56. Rostovtseva T. K., Tan W., Colombini M.On the role of VDAC in apop-tosis: fact and fiction. J. Bioenerg. Biomembr. 2005; 37 (3): 129—142.
57. Antonsson B., Montessuit S., Lauper S. et al.Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem. J. 2000; 345 (Pt 2): 271—278.
58. Letai A., Bassik M. C., Walensky L. D. et al.Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2 (3): 183—192.
59. Griffiths E. J., Halestrap A. P.Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J. Mol. Cell Cardiol. 1993; 25 (12): 1461 — 1469.
60. Zorov D. B., Kinnally K. W., Tedeschi H.Voltage activation of heart inner mitochondrial membrane channels. J. Bioenerg. Biomembr. 1992; 24 (1): 119—124.
61. Dana A., Yellon D. M.ATP dependent K+ channel: a novel therapeutic target in unstable angina. Eur. Heart J. 1999; 20 (1): 2—5.
62. Mentzer R. M., Rahko P. S., Molina-Viamonte V. et al.Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am. J. Cardiol. 1997; 79 (12A): 38—43.
63. Mahaffey K. W., Puma J. A., Barbagelata N. A. et al.Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 1999; 34 (6): 1711 — 1720.
64. Vanden Hoek T., Becker L. B., Shao Z. H. et al.Preconditioning in car-diomyocytes protects by attenuating oxidant stress at reperfusion. Circ. Res. 2000; 86 (5): 541—548.
65. TangX. L., Takano H., Rizvi A. et al.Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits. Am. J. Physiol. Heart Circ. Physiol. 2002; 282 (1): H281—H291.
66. Ogawa T., Nussler A. K., Tuzuner E. et al.Contribution of nitric oxide to the protective effects of ischemic preconditioning in ischemia-reper-fused rat kidneys. J. Lab. Clin. Med. 2001; 138 (1): 50—58.
67. Васильева А. К., Плотников Е. Ю., Казаченко А. В. и соавт.Ингибиро-вание GSK-^e снижает индуцированную ишемией гибель клеток почки. Бюл. эксперим. биологии и медицины 2010; 149 (3): 276—280.
68. Schultz J. J., Hsu A. K., Gross G. J.Ischemic preconditioning and morfin-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J. Mol. Cell Cardiol. 1997; 29 (8): 2187—2195.
69. Bell S. P., Sack M. N., Patel A. et al.Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J. Am. Coll. Cardiol. 2000; 36 (7): 2296—2302.
70. Лихванцев В. В.Интраоперационная органопротекция как необходимый компонент сбалансированной анестезии: автореф. дисс. &#8230; д.м.н. М., 1991. 37.
71. С^^&#8217;пB. A., Gamperl A. K., Slocum R. E., Hickey R. F.Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocar-dial infarct size in rabbits. Anesthesiology 1997; 87 (5): 1182—1190.
72. Kersten J. R., Schmeling T. J., Pagel P. S. et al.Isoflurane mimics ischemic preconditioning via activation of K (ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997; 87 (2): 361—370.
73. Minguet G., Joris J., Lamy M.Preconditioning and protection against ischemia-reperfusion in non-cardiac organs: a place for volatile anaesthetics? Eur. J. Anaesthesiol. 2007; 24 (9): 733—745.
74. Плотников Е. Ю.Митохондрия как центральное звено защитных и повреждающих сигнальных путей при развитиии почечной недостаточности: автореф. дисс. д.м.н. М., 2009. 395.
75. Ломиворотов В. В., Пономарев Д. Н., Шмырев В. А. и соавт.Применение дистанционного ишемического прекондиционирования у кардио-хирургических больных. Общая реаниматология 2011; VII (3): 63—69.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.